Abiopharma

🔍 Curnes Nelson Bunker (Executive)

Company: Mobia Medical, Inc. (MOBI)

Report Date: 2026-01-30

Detailed Transactions and Holdings:

• Acquired 283,895 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | shares_owned_after: 303,322.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 13,684 shares of Common Stock at $14.653 per share (Direct)
  Date: 2026-05-11 | Code: X | equity_swap_involved: 0 | shares_owned_after: 317,006.00 | transaction_form_type: 4
• Sold 13,368 shares of Common Stock at $15.0 per share (Direct)
  Date: 2026-05-11 | Code: F | equity_swap_involved: 0 | shares_owned_after: 303,638.00 | transaction_form_type: 4
• Acquired 5,742 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | shares_owned_after: 5,742.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 476,485 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | shares_owned_after: 476,485.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 333,333 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | shares_owned_after: 809,818.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 175,077 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | shares_owned_after: 175,077.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 166,666 shares of Convertible Notes (Derivative)
  Date: 2026-01-30 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,000,000.00 | transaction_form_type: 4 | Footnotes: F2, F3, F2, F2
• Acquired 333,333 shares of Convertible Notes (Derivative)
  Date: 2026-01-30 | Code: A | equity_swap_involved: 0 | shares_owned_after: 4,000,000.00 | transaction_form_type: 4 | Footnotes: F2, F3, F2, F2
• Acquired 8,411 shares of Convertible Notes (Derivative)
  Date: 2026-02-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,100,937.62 | transaction_form_type: 4 | Footnotes: F2, F3, F2, F2
• Acquired 206,070 shares of Stock Option at $15.0 per share (Derivative)
  Date: 2026-05-07 | Code: A | Expires: 2036-05-07 | equity_swap_involved: 0 | shares_owned_after: 206,070.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 54,932 shares of Series A Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Sold 28,710 shares of Series C Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Sold 110,058 shares of Series D Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Sold 8,374 shares of Series E-1 Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Sold 81,821 shares of Series F Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Sold 5,742 shares of Series C Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Sold 145,067 shares of Series D Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Sold 78,171 shares of Series E-1 Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Sold 171,179 shares of Series E-2 Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Sold 82,068 shares of Series F Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Sold 6,890 shares of Warrants at $14.653 per share (Derivative)
  Date: 2026-05-11 | Code: X | Expires: 2033-06-13 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F5, F5
• Sold 6,794 shares of Warrants at $14.653 per share (Derivative)
  Date: 2026-05-11 | Code: X | Expires: 2033-05-24 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F5, F5
• Sold 175,077 shares of Convertible Notes (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F2, F2, F2
• Sold 333,333 shares of Convertible Notes (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F2, F2, F2

Footnotes:

• F1: Each share of the Series A, Series C, Series D, Series E-1, Series E-2 and Series F Preferred Stock converted into Common Stock immediately prior to the completion of the Issuer's initial public offering (the "Offering") pursuant to its terms.
• F2: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Offering. The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes.
• F3: This transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended, in connection with the Offering, and is reported herein pursuant to Rule 16a-2(a).
• F4: The stock option will vest as to 25% of the underlying shares on May 7, 2027, and will vest thereafter in 36 substantially equal monthly installments.
• F5: The warrants are currently exercisable. In connection with the Offering, the warrants were exercised according to the terms of the applicable warrant agreement. The warrants have a net exercise provision under which the Reporting Person may, in lieu of payment of the exercise price in cash, surrender the warrants and receive a net amount of shares based on the fair market value of the shares at the time of exercise of the warrants after deduction of the aggregate exercise price.